
Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLC
ADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.
Antibody-drug conjugates (ADCs) directed at targets such as B7-H3 and SEZ6, including ifinatamab deruxtecan and ABBV-706, are being evaluated in relapsed small cell lung cancer (SCLC), a setting in which DLL3-targeted bispecific T-cell engagers such as tarlatamab are also changing care.
Anne Chiang, MD, PhD, spoke with CancerNetwork® about a presentation she gave at the 44th Annual Chemotherapy Foundation Symposium (CFS®), hosted by Physicians’ Education Resource®, LLC, which was titled “Small Cell Updates: Steps Backward, Leaps Forward.” She focused on how these ADCs may compete with or complement DLL3-targeted bispecifics, why the biology of B7-H3 as an immune checkpoint is of interest in SCLC, and how sequencing and combinations may be approached.
Chiang is an associate professor of Medicine in the Section of Medical Oncology; associate cancer center director of Clinical Initiatives; and vice chief of Clinical Affairs, Medical Oncology and Hematology at Yale School of Medicine.
Transcript:
CancerNetwork: B7-H3 ADCs such as ifinatamab deruxtecan and SEZ6 ADCs like ABBV-706 have shown encouraging activity in relapsed disease. How do you see these competing with or complementing DLL3-targeted bispecifics?
Chiang: All these ADCs look super exciting. There’s B7-H3, SEZ6, DLL3, and also TROP2. They all have response rates in the 40% to 60% range in heavily pretreated populations. If you look just at the patients who’ve had one line of treatment, they’re sometimes going up to around 80% or higher.
I think B7-H3 is interesting because it’s not just important to think about the target and where the ADC docks, but also the biology of where it’s docking. B7-H3 is an immune checkpoint. In small cell [lung cancer], and this is work that’s been done at Yale by Kurt Schalper, MD, PhD, my collaborator, PD-L1 is generally not expressed in the tumor cells, but B7-H3 is expressed in about 65% of small cell tumors. It may be that by targeting B7-H3, we’re not only getting the chemotherapy to the tumor cell, but we’re also disrupting the immunobiology of the tumor, so that the cancer cells are more visible to the immune system.
The bottom line is that we’re going to learn a lot about these different ADCs, and I think they’ll be important in sequencing. If you have an ADC that works for a while and then you develop resistance, you might want to switch to an ADC with a different target. Or if you develop resistance on tarlatamab, which docks to DLL3, perhaps you want to use an ADC that looks at a different target. The sequencing of different agents will be important…It may be that you want to combine an ADC with a T-cell engager, one that targets DLL3 and another that targets B7-H3 or SEZ6. We need to learn more about this, but it’s very exciting because we have different ways of tickling those tumor cells to induce cell death.
Related to this article








